MRUS News and Press, Merus N.V. From 05/26/21

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg...

Yesterday, after the close, Merus (MRUS) updated interim data for its bispecific antibody zenocutuzumab (Zeno) in a phase 1/2 eNRGY trial targeting patients with NRG1+ cancers.The data was included in an abstract related to a presentation at the upcoming American Society of Clinical...

Gainers: Big Rock Partners Acquisition (BRPA) +86%.Euro Tech Holdings (CLWT) +32%.Urban One (UONE) +28%.Sensei Biotherapeutics (SNSE) +28%.BBQ Holdings (BBQ) +22%.PDS Biotechnology (PDSB) +20%.Advanced Emissions Solutions (ADES) +19%.Progenity (PROG) +18%.Moxian (MOXC) +16%.Precipio (PRP...

Merus N.V. (MRUS) highlighted the benefit of Zenocutuzumab in pancreatic cancer with the announcement of an abstract regarding the experimental cancer therapy which is part of a presentation at the American Society of Clinical Oncology ((ASCO)) 2021 Annual Meeting.The interim data a...

-   51 patients with NRG1+ cancer have been treated, including 33 patients evaluable for response, as of the January 12, 2021, data cutoff date -   Encouraging early clinical activity observed, with confirmed partial responses in 4 of 10 patients with pancreatic cancer...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced new collaborat...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chi...

Merus (MRUS): Q1 GAAP EPS of -$0.28 misses by $0.10.Revenue of $8.35M (+32.5% Y/Y) misses by $9.7M.Press Release For further details see: Merus EPS misses by $0.10, misses on revenue

Merus N.V. (MRUS) announces that the first patient has been treated in its phase 1/2 dose escalation and expansion trial evaluating MCLA-129 for the treatment of patients with advanced non-small cell lung cancer ((NSCLC)) and other solid tumors.The phase 1/2, open-label clinical trial of...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific ...